Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 14, 1997

View Archived Issues

Annual Report: CellPro

Annual Report: Cangene

ZymoGenetics/Novo Nordisk isolate anticlotting agent

EPO activators/agonists described by J&J and Affymax

X-ray contrast agents from Schering AG

Human Genome Sciences describes MCP-4 polypeptide

Anti-factor Xa compounds disclosed by RPR

Zeneca describes ET antagonists

Retinoid series for cancer

BASF prepares dolastatin derivatives

TK inhibitors disclosed by RCT

HMR synthesizes potent AChE inhibitor

Combination Remune/triple anti-HIV therapy trial begins

Neuraminidase inhibitor holds promise for flu

Approval anticipated for TMR using Heart Laser

Biopharmaceutics/ABS form advisory team to advance filings for anticancer drug

Alza/Alkermes stock purchase and development agreements

Clinical development of HIV immunotherapeutic advances

Gliatech's ADCON-L nears FDA approval

Nymox drug candidate for AD to enter phase I

Inex and Schering-Plough complete research collaboration

Positive phase I safety profile for Immunex's new product candidate

Dermik launches new acne medication

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 28, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 28, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Muted and missing M&As: JPM deals absent in 2026
BioWorld
For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...